Pioglitazone

Hmm… We’d better think about this again. Pioglitazone is not a good first‑line choice because it causes weight gain and fluid retention and it lacks clear cardiovascular outcome benefits. If a thiazolidinedione is considered at all, it is considered in cases where first line drugs are not indicated or unavailable, or in combination with other first line drugs.

Try to think about other drugs with favourable weight and cardiovascular profiles. Always consider the full clinical context when prescribing medications and try again!

  • Omalizumab (IgE antibody)/Salbutamol (SABA) [undo]
  • Bivalirudin (direct thrombin inhibitor) [undo]
  • Digoxin [undo]
  • Enalapril (ACE inhibitor) [undo]
  • Introduction to the profession and to other students [undo]
  • Decreased absorption of dietary cholesterol [undo]
  • Salbutamol (SABA) [undo]
  • History of Present Illness [undo]
  • Η ποιότητα ζωής του ασθενούς χειροτερεύει [undo]
  • Give Nurse Instruction [undo]
  • Opțiunea 1 [undo]
  • High Molecular Weight Heparin [undo]
  • patient at risk! [undo]
  • Bedside Ultrasound Examination [undo]
  • Pioglitazone [undo]

Map: Michael Green_GEMD_1 (1115)
Node: 21091
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway